The Significance of an Increased Beta-Hydroxybutyrate at Presentation to the Emergency Department in Patients with Diabetes in the Absence of a Hyperglycemic Emergency by Depczynski, B et al.
Hindawi
Journal of Diabetes Research
Volume 2019, Article ID 7387128, 6 pages
https://doi.org/10.1155/2019/7387128Research Article
The Significance of an Increased Beta-Hydroxybutyrate at
Presentation to the Emergency Department in Patients with
Diabetes in the Absence of a Hyperglycemic EmergencyBarbara Depczynski ,1 Alexandra Tze Kiu Lee,1 Wayne Varndell,2 and Angela L. Chiew2
1Endocrinology Department, Prince of Wales Hospital, Randwick, NSW, Australia
2Emergency Department, Prince of Wales Hospital, Randwick, NSW, Australia
Correspondence should be addressed to Barbara Depczynski; barbara.depczynski@health.nsw.gov.au
Received 31 July 2019; Accepted 22 September 2019; Published 10 October 2019
Academic Editor: Steven F. Abcouwer
Copyright © 2019 Barbara Depczynski et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The significance of hyperketonemia in adults with diabetes presenting to the emergency department with acute illness, not due to a
diabetic hyperglycemic emergency, has not been well characterized. Adult patients with diabetes presenting to the emergency
department who had venous blood gas and beta-hydroxybutyrate levels measured whilst in the emergency department were
retrospectively evaluated for the relationship between BHB and clinical outcomes. Over 6months, 404 patients with diabetes
had at least one beta-hydroxybutyrate level measured in the emergency department. There were 23 admissions for diabetic
ketoacidosis (DKA) or hyperosmolar state. Of the remainder, 58 patients had a beta-hydroxybutyrate ≥ 1mmol/L; this group
had a higher glucose at presentation (19.0 (8.8) versus 10.4 (9.9) mmol/L), higher HbA1c (8.8 (5.4) versus 8.0 (3.3)%), lower
bicarbonate (22.6 (6.2) versus 24.8 (4.7) mmol/L), and higher anion gap (14.8 (6.1) versus 12.6 (4.2)) than had those with BHB
< 1mmol/L. There was no association between the presence of ketosis and the length of stay (4.2 (7.3) versus (3.0) (7.2) days).
Acute illness in those with diabetes associated with ketosis in the absence of DKA is associated with worse glycaemic control
than in those without ketosis. Ketosis may represent an intermediate state of metabolic dysregulation rather than being
associated with a more severe acute illness, as suggested by no relationship between BHB and length of stay.1. Introduction
Ketone bodies—beta-hydroxybutyrate (BHB), acetoacetate,
and acetone—are an important energy source during energy
restriction. They are predominately produced from fatty acids
by the liver [1]. The prevalence and clinical significance of
ketosis in acute illness in adult patients with diabetes, in the
absence of a hyperglycemic emergency, have not been well
defined. The degree of BHB elevation with hyperglycemic
emergencies has been well characterised, with BHB level > 3
mmol/L in children or >3.8mmol/L in adults being presump-
tive evidence of diabetic ketoacidosis [2]. Normally, circulat-
ing BHB levels are below 0.5mmol/L [1], but with starvation,
levels can rise up to 6mmol/L [3]. A study performed in a pae-
diatric population presenting to the ED found an association
between ketone levels and fever, and ketone levels were higherin children who were admitted [4]. This suggests that ketosis
occurs as part of a stress response to illness. BHB, in addition
to its traditional role as a fuel source during fasting, also has
an important role as a signalling link between the metabolic
and immune systems [1]. There is a paucity of information
about the expected degree of ketosis in adults with acute
illness. Defining the expected degree of ketosis with acute
illness has becomemore important given the ability to under-
take point-of-care BHB testing [5] and that sodium glucose
cotransporter type 2 inhibitors (SGLT2i) may precipitate
euglycaemic DKA with intercurrent illness [6].
The objectives of this study are to examinewhether ketosis
is associated with greater metabolic derangement by examin-
ing the relationship between BHB and glucose, HCO3, anion
gap (AG), and base excess (BE) and whether ketosis is associ-
ated with a more severe acute illness, as determined by an
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tate at presentation. In order to explore whether BHB may
be part of a systemic stress response, the frequency of systemic
inflammatory response syndrome (SIRS) [7] according to the
presence of ketosis will be assessed.
2. Methods
2.1. Design and Setting. The study population consisted of
adult patients attending the ED of Prince of Wales Hospital,
a tertiary referral teaching hospital in an urban area of Aus-
tralia. Patients were eligible if a point-of-care (POC) BHB
measurement and venous blood gas (VBG) measurement
had been performed at presentation to the ED. BHB testing
had been encouraged in the ED due to reports of euglycaemic
DKA, given the increased use of sodium glucose cotranspor-
ter type 2 inhibitors (SGLT2i) in the community [6].
2.2. Data Extraction. Demographic data, as well as clinical
and laboratory variables obtained at the time of the presenta-
tion and captured in the electronic medical record (Cerner
Millennium), were retrospectively retrieved and used for this
analysis. We collected epidemiological information (age,
gender, length of stay, and admitting team), medical history
(diabetes management at presentation and presence of
comorbidities to determine the Charlson score [8], as well
as the presence of other contributors to risk for ketosis
including reduced oral intake or ethanol intake), biochemical
characteristics (glucose, BHB, lactate, anion gap (AG), base
excess (BE), estimated glomerular filtration rate (eGFR),
and white cell count (WCC)), and clinical observations at
presentation (heart rate, blood pressure, and temperature).
VBG measurements were performed using ABL800 Flex
(Radiometer Medical ApS, Denmark). BHB levels were mea-
sured using a POC machine (Nova Biomedical Corporation,
USA), which has been well validated against laboratory mea-
surement [5]. AG was calculated by subtracting the sum of
chloride and bicarbonate concentration from the sum of
sodium and potassium concentration [9]. The presence or
absence of diabetes was as documented in the admission or
discharge summary and included new diagnoses made dur-
ing that admission. Reduced oral intake, vomiting, or acute
ethanol intake was recorded if documented in the medical
record. DKA and HHS were defined by Kitabchi et al. [10]
with the triad of metabolic acidosis, hyperglycemia, and keto-
sis, although the measurement of BHB was performed using
POC BHB level rather than by laboratory measurement
[2, 3]. Euglycaemic DKA was defined by Kitabchi et al. [10]
but again with BHB measured using a POC machine.
Systemic inflammatory response syndrome (SIRS) is an
inflammatory process, independent of its cause seen in a
range of conditions including sepsis [7]. It was defined as
two or more of the following: temperature < 36°C or >38°C,
respiratory rate > 20 breaths/min, heart rate > 90 beats/-
minute, WCC < 4 × 109/L or >12 × 109/L, or >10% band
forms [7]. Data to calculate Quick Sequential (sepsis-related)
Organ Failure Assessment (qSOFA) were also collected, with
2 or more of the following variables considered as a positive
score: respiratory rate ≥ 22/minute, systolic blood pressure≤ 100mmHg, or altered mentation [11]. The presence of
preexisting comorbid conditions was defined by the Charlson
comorbidity index score [8].
2.3. Analysis. Since BHB levels not higher than 0.9mmol/L
were seen in patients on SGLT2i [12], BHB does not exceed
1mmol/L, irrespective of glucose in the absence of intercur-
rent illness in T1DM[13], andhyperketonemia has previously
been defined at a threshold of 1mmol/L regardless of diabetes
status [3], patients were grouped according to whether BHB
level was <1mmol/L (low-BHB group or no-ketosis group),
or BHB was ≥1mmol/L without DKA (high-BHB group or
ketosis group), or the presence of DKA or HHS.
Data were expressed as the medians and interquartile
ranges (IQRs), as the mean and standard deviation, or as
percent. Statistics were obtained using SPSS version 25
(IBM SPSS Statistics for Windows, version 25.0 Armonk,
NY, IBM Corporation). The Kruskal-Wallis H test was used
for comparisons between groups for continuous variables.
Where there were significant differences, post hoc analysis
was performed using Dunn’s procedure with a Bonferroni
adjustment. For categorical variables, a χ2 test was
performed. Ethics approval was obtained from South Eastern
Sydney Local Health District Human Research Ethics
Committee, who waived the need for consent.
3. Results
3.1. Number and Characteristics of Participants. Over a
6-month period in 2018, 404 patients with diabetes present-
ing to the ED had at least one VBG level and one BHB level
measured whilst in the ED. There were 23 diabetes emergen-
cies in total, including DKA in 12 patients with T1DM, DKA
due to a SGLT2i in a patient with T2DM, DKA in 2 patients
with T2DM, and DKA in 2 patients with diabetes due to exo-
crine pancreatic disease; HHS was present in 6 cases. Three
hundred twenty-three patients had BHB below 1mmol/L,
and 58 patients had BHB ≥ 1mmol/L but without DKA.
The median age was 71.7 (range 16.3-102.3) years. 57.3%
of the cohort were men. The median length of stay (LOS) was
3.0 (range 0.5-77.8) days. 76% of the cohort were admitted to
the hospital, the majority under a medical team, with both
the low- and high-ketone groups containing a similar pro-
portion of surgical patients (12.4 and 8.6%). For the whole
cohort, median glucose was 12.6 (IQR, 8.5-19.4) mmol/L,
median lactate was 1.9 (IQR 1.5-2.8) mmol/L, and median
BHB was 0.2 (IQR 0.1-0.6) mmol/L.
Demographic features of the cohort, stratified for ketone
and diabetic emergency status, are shown in Table 1. Those
presenting with DKA were younger (median age was 48.9
years, but there were no differences between the other
groups). T1DM was the most frequent type of diabetes in
the DKA group, but otherwise, the types of diabetes did not
vary between the low- and high-ketone groups. The
frequency of insulin use did not differ across the groups,
and the overall use of SGLT2i was low, 3.4 and 5.2% of the
low- and high-ketone groups, respectively. The burden of
preexisting comorbidities, as reflected by the Charlson score,
was similar across the groups.
Table 1: Characteristics of patients with diabetes presenting to the emergency department, stratified by beta-hydroxybutyrate category or






Number (%) 323 (79.9) 58 (14.4) 17 (4.2) 6 (1.5)
Age year median (IQR)∗ 72.2 (22.5) 63.4 (34.3) 48.9 (44.6)# 77.1 (39.6)
Men (%)∗ 57.6 60.3 61.1 0
Type of diabetes (%)∗
T1 12.1 19.0 72.2 0
T2 83.9 72.4 16.7 100
T3 2.8 5.2 11.1 0
Use of SGLT2i at presentation (%) 3.4 5.2 0 0
Use of insulin at presentation (%) 52.8 53.4 81.3 33.3
Admitting team
Surgery 10.5 10.3 - -
Cardiac 12.4 8.6 - -
Respiratory 7.4 5.2 - -
Geriatric 12.1 17.2 - 33.3
Other medical 30.0 31.0 100 66.7
Discharge from ED 25.7 25.9 - -
Length of stay median (IQR) 3.0 (7.2) 4.2 (7.3) 3.2 (4.1) 3.5 (10.5)
In-hospital death percent 5.1 5.3 4.9 8.6
Reduced oral intake at presentation∗ (%) 15.2 32.8 55.6 16.7
Vomiting at presentation∗ 13.6 19 72.2 0
Acute ethanol at presentation∗ (%) 3.4 8.6 16.7 0
SIRS∗ (%) 22.6 41.4 44.4 50.0
qSOFA (%)
p = 0:412 1.9 5.2 0 0
Charlson score
Arbitrary units (IQR)
3 (2) 2.8 (2.0) 2.1 (1.5) 1.4 (1.5)
Glucose∗ (mmol/L)
Median (IQR)
10.4 (9.9) 19 (8.8)# 29.8 (14.4)# 30.4 (12)#
Beta-hydroxybutyrate (mmol/L)
Median (IQR)
0.2 (0.3) 2.1 (1.5) 6.3 (0.4) 1.5 (3.0)
Lactate (mmol/L)
Median (IQR)
2.3 (1.8) 2.4 (2.2) 2.1 (0.2) 1.9 (1.0)
eGFR (mL/min/1.73m2)
Median (IQR)
57.5 (53) 65 (58) 75 (36) 55 (48)
Bicarbonate∗ (mmol/L)
Median (IQR)
24.8 (4.7) 22.6 (6.2)# 12.3 (5.0)# 24.8 (9.4)
Anion gap∗
Median (IQR)
12.6 (4.2) 14.8 (6.1)# 27.1 (6.0)# 17.2 (5.9)
Standard base excess∗ 0.6 (4.3) -1.8 (6.5)# -14 (5.6)# 0.3 (8.9)
HbA1c∗ (%)
Median (IQR)
8.0 (3.3) 8.8 (5.4)# 9.4 (1.3)# 14.0 (9.1)#
WCC∗ (cells/μL)
Mean (IQR)
10.2 (5.9) 12.7 (6.1)# 15.5 (9.0)# 10.5 (4.6)
∗p < 0:05 across groups. #p < 0:05 compared with the no-ketosis group.
3Journal of Diabetes Research3.2. Relationship between BHB and Metabolic State. There
was a positive correlation between BHB and glucose
(r = 0:349, p = 0:0005). With the exclusion of those with
DKA or HHS, there was a negative correlation betweenBHB and HCO3 (r = ‐0:317, p = 0:0001) and a positive corre-
lation between BHB and anion gap (r = 0:253, p = 0:0001).
HCO3 and BE were the lowest in the DKA group, but they
were lower in the ketosis group as compared with the
4 Journal of Diabetes Researchno-ketosis group. Similarly, AG was the highest in the DKA
group, but it was higher in the ketosis group versus
no-ketosis group. HbA1c was the highest in those presenting
with HHS (14.0 (9.1) %); the HbA1c of the ketosis group was
higher than that of the no-ketosis group (8.8 (5.4) versus
8.0 (3.3) %, p < 0:05). The glucose at presentation in those
with ketosis was higher than that in those without ketosis
(19.0 (8.8) versus 10.4 (9.9) mmol/L, p < 0:05). The median
BHB of those on insulin at admission was no different to that
of those not on insulin at admission (0.2 (0.4) versus 0.2 (0.3)
mmol/L), and similarly, BHB was not different for those on
or not on a SGLT2i (0.2 (0.3) versus 0.3 (0.8) mmol/L).
3.3. Severity of Acute Illness and Other Relationships with
BHB. The LOS did not differ between the ketone groups, as
shown in Table 1 (median LOS for the low-ketone group
was 3.0 (7.2) days, for the high-ketone group 4.2 (7.3) days,
and for the DKA group 3.2 (4.1) days). There were no differ-
ences in inpatient mortality across the ketone groups. LOS
correlated with lactate (r = 0:125, p = 0:013) but not with
BHB (r = 0:063). The frequency of SIRS was the lowest in
those free of ketosis (22.6%), with a similar frequency in the
other groups (41.4-50%). The median BHB of the high-
ketone group was 0.4 (0.9) mmol/L versus 0.2 (0.3) mmol/L
in the no-ketosis group (p < 0:01). The qSOFA score did
not differ between the groups. WCC was the highest in those
with ketosis or DKA, as shown in Table 1. The frequency of
documented acute ethanol intake was the highest amongst
those presenting with DKA (16.7%) and the next highest in
those with ketosis (8.6%). In none of these cases was ketosis
ascribed to a diagnosis of alcoholic ketoacidosis. Patients with
ketosis or DKA were likely to have reduced oral intake or
vomiting as documented at presentation, as shown in Table 1.
4. Discussion
Hyperketonemia defined as BHB ≥ 1mmol/L, in the absence
of a diagnosis of DKA or HHS, was present in 14% of this
series of patients with diabetes attending an adult emergency
department who had VBG and BHB levels measured. Results
of HCO3, AG, and BE for those with ketosis were intermedi-
ate between those without ketosis and those with DKA.
Those with ketosis had poorer prior glycaemic control, as
reflected by a higher HbA1c than in those without ketosis,
and had greater acute hyperglycemia on presentation. These
results suggest that ketosis in the absence of a diabetic emer-
gency reflects in a vulnerable patient greater metabolic
decompensation with acute illness rather than severity of
acute illness as reflected by LOS, which was not different
between the low- and high-ketone groups.
The rate of ketosis in our cohort is lower than that seen in
acutely unwell children without diabetes presenting to the
ED, where those with BHB ≥ 1:2mmol/L or higher
comprised 34.4% of the cohort [4]. However, the frequency
of hyperketonemia in ED in our series was higher than that
seen amongst patients without diabetes fasting for surgical
procedures, where it was only 3% [14]. This difference in
the rate of ketosis may suggest that fasting or reduced oral
intake alone is not responsible for the development of ketosis.Adults with diabetes, especially if poorly controlled, or with
hyperglycemia may warrant undergoing BHB testing in the
presence of acute illness. Amongst those with type 1 diabetes
and diabetes due to pancreatic disease, where there is hyper-
glycemia or concern for diabetic ketoacidosis due to meta-
bolic acidosis or symptoms of ketosis such as nausea and
vomiting, BHB testing is warranted. Given the severity of
outcomes with SGLT2i-induced DKA in prior reports [6],
BHB testing in any patient presenting acute illness on this
class of drug would be prudent even though the ketone level
in those on this drug did not differ from those not on a
SGLT2i. In the presence of an unexplained metabolic acido-
sis, BHB testing may help with the diagnostic workup.
Those with ketosis, DKA, or HHS had poorer prior
glycaemic control, as reflected by higher HbA1c, and had
greater hyperglycemia on presentation. Hyperglycemia and
T2DM are associated with higher BHB levels in the absence
of acute illness [15]. We did not see a relationship between
BHB and LOS, suggesting that the occurrence of ketosis
does not reflect a more severe acute presentation. In
support of this, lactate correlated with LOS, but there was
no relationship between BHB and LOS. We had assessed
lactate as a surrogate marker or a predictor of poorer
hospital outcomes and more severe illness at presentation
[16], but we did not collect data on whether type A or B
hyperlactatemia may have been present.
Aside from its role as an alternate fuel source, there is also
evidence that BHB provides a signalling link between the
metabolic and immune systems [1]. There is substantial
evidence for an increase in inflammation occurring under
conditions of hyperketonemia [17]. Increased levels of the
ketone body acetoacetate result in increased oxidative stress
in red blood cells as shown by increased lipid peroxidation
and reduced glutathione [18]. Hyperketonemia can also
increase tumour necrosis factor alpha secretion [19] and
increase monocyte adhesion to vascular endothelium [20].
Acetoacetate has been shown to upregulate NADPH oxidase
4, contributing to oxidative stress of endothelial cells [21].
Although we have shown an association between BHB and
SIRS, our method limits any further interpretation. The SIRS
response did not reflect sepsis given that the qSOFA scores
were not different between the groups. Potentially, the com-
ponents of SIRS in our series may have been abnormal due
to volume contraction due to reduced oral intake or an
increased respiratory drive may have arisen in response to
an increased anion gap. However, in a paediatric cohort fast-
ing for surgery, lower ketosis was associated with a better
mean arterial pressure [22], suggesting that ketonemia in
itself is potentially harmful to the haemodynamic state. An
inverted U-shaped relationship between BHB and physiolog-
ical effects has been proposed with mild elevation being
beneficial and higher levels being harmful [23].
The frequency of ketosis varied with the acute nutritional
state. This finding is similar to that from a paediatric ED
where a strong correlation between BHB levels and reduced
oral intake was found [4]. It is unclear whether the develop-
ment of ketosis contributed to reduced intake and vomiting
in our ketosis cohort. Although no patient in our series was
given a diagnosis of alcoholic ketoacidosis, a high rate of
5Journal of Diabetes Researchdocumented acute ethanol intake prior to presentation in the
DKA and ketosis groups was seen. It has been suggested that
cases of alcoholic ketoacidosis may be missed or underre-
ported in the ED with presentation ascribed to other diagno-
ses such as acute gastritis [24], and so BHB testing may be
useful if this is suspected.
Our study has several limitations, particularly that the
data are observational, limiting any conclusions on causality.
Patients with diabetes that remained undiagnosed may not
have been included. It is unknown whether the BHB result
influenced glycaemic management and, thus, outcomes.
LOS as a reflection of severity of presentation is open to
confounders such as comorbidities; however, we attempted
to address this by assessing the Charlson score, which did
not differ between the groups. SIRS as a marker of inflamma-
tion or stress response is nonspecific [7], and as discussed, the
score may instead reflect physiological responses to the
metabolic derangements. A further limitation is that acetoa-
cetate measurement was not assessed. Acetoacetate measure-
ment can be helpful in the assessment of patients with
increased BHB and acute illness [17].
In conclusion, this study shows that ketosis may be seen
with acute illness in adults with diabetes. Ketosis may repre-
sent an intermediate stage of metabolic derangement in
association with acute illness. Ketosis is associated with the
presence of SIRS at hospital presentation, and whether ketosis
is part of an acute stress response requires further exploration.
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